A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2005
At a glance
- Drugs Celecoxib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Nov 2005 New trial record.